Difference between revisions of "Bevacizumab (Avastin)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.<ref name="insert">[http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf Bevacizumab (Avastin) package insert]</ref><ref>[ | + | Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.<ref name="insert">[http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf Bevacizumab (Avastin) package insert]</ref><ref>[[Media:Bevacizumab.pdf | Bevacizumab (Avastin) package insert (locally hosted backup)]]</ref><ref>[http://www.avastin.com Avastin manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
| + | *[[Cervical cancer]] | ||
| + | *[[Colon cancer]] | ||
| + | *[[Esophageal cancer]] | ||
| + | *[[Hepatobiliary cancer]] | ||
| + | *[[Non-small cell lung cancer]] | ||
| + | *[[Ovarian cancer]] | ||
| + | *[[Renal cancer]] | ||
| + | *[[Unknown primary]] | ||
==Information about counterfeit Bevacizumab (Avastin)== | ==Information about counterfeit Bevacizumab (Avastin)== | ||
| Line 12: | Line 23: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/ | + | *[http://chemocare.com/chemotherapy/drug-info/bevacizumab.aspx Bevacizumab (Avastin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/bevacizumab.aspx Bevacizumab (Avastin) patient drug information (Chemocare)]</ref> |
| + | *Brief patient counseling information can be found on [http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf#page=22 pages 22-23 of the package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/bevacizumab-patient-drug-information Bevacizumab (Avastin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bevacizumab-patient-drug-information Bevacizumab (Avastin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/bevacizumab-patient-drug-information Bevacizumab (Avastin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bevacizumab-patient-drug-information Bevacizumab (Avastin) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 18:03, 7 October 2012
General information
Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Breast cancer
- Cervical cancer
- Colon cancer
- Esophageal cancer
- Hepatobiliary cancer
- Non-small cell lung cancer
- Ovarian cancer
- Renal cancer
- Unknown primary
Information about counterfeit Bevacizumab (Avastin)
- FDA's 2/14/2012 statement about counterfeit Avastin in U.S.
- Genentech's 2/14/2012 statement on counterfeit drug labeled as Avastin (Bevacizumab) in the United States - contains pictures of authentic and counterfeit product
- Authorized specialty distributors, wholesalers and specialty pharmacies for Bevacizumab (Avastin)
Patient drug information
- Bevacizumab (Avastin) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on pages 22-23 of the package insert[1]
- Bevacizumab (Avastin) patient drug information (UpToDate)[5]